Posts

Menarini licenses Gan & Lee’s biweekly GLP-1 drug for Europe

on

Roche licenses Simcere’s trispecific T-cell engager in deal worth up to $1.53 billion

on

Lilly’s Deal Spree Broadens Biotech Investor Paydays

on

Roche’s Genentech signs ADC partnership with DualityBio worth over $1 billion

on

Osivax licenses GC Biopharma’s flu vaccine to pursue a single-shot combination vaccine

on

Haisco licenses immunology asset to new U.S. biotech Sentivera in deal worth up to $1.5 billion

on

Haisco Signs Potential $1.5B Sentivera Deal

on

Sentivera launches with potential $1.5B Haisco inflammatory-disease deal

on

Roche Bets Up to $2.3 Billion on Hanmi’s Muscle-Preserving Obesity Drug

on

Ying Huang's post-Legend Life Takes Shape at K2 With $250M Goal to License Asia Assets

on

The NewCo Model in Chinese Biotech: A Transformative Exit Strategy for Global Expansion

on

Fosun Pharma's Global Ambitions: Innovation-Driven Expansion in 2025

on

Crescent Biopharma and Kelun-Biotech Announce Reciprocal Licensing Pact for PD-1xVEGF and ADC Cancer Therapies

on

Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale

on

Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends

on

Getting to Yes: How Deal-Making Fuels Biotech Growth – 2025 Updates

on

GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China's Hengrui Pharma

on

Alphabet's Calico Strikes $596M Deal for Mabwell's Anti-Aging Antibody

on